TINAGL1 and B3GALNT1 are potential therapy target genes to suppress metastasis in non-small cell lung cancer

BMC Genomics. 2014;15 Suppl 9(Suppl 9):S2. doi: 10.1186/1471-2164-15-S9-S2. Epub 2014 Dec 8.

Abstract

Background: Non-small cell lung cancer (NSCLC) remains lethal despite the development of numerous drug therapy technologies. About 85% to 90% of lung cancers are NSCLC and the 5-year survival rate is at best still below 50%. Thus, it is important to find drugable target genes for NSCLC to develop an effective therapy for NSCLC.

Results: Integrated analysis of publically available gene expression and promoter methylation patterns of two highly aggressive NSCLC cell lines generated by in vivo selection was performed. We selected eleven critical genes that may mediate metastasis using recently proposed principal component analysis based unsupervised feature extraction. The eleven selected genes were significantly related to cancer diagnosis. The tertiary protein structure of the selected genes was inferred by Full Automatic Modeling System, a profile-based protein structure inference software, to determine protein functions and to specify genes that could be potential drug targets.

Conclusions: We identified eleven potentially critical genes that may mediate NSCLC metastasis using bioinformatic analysis of publically available data sets. These genes are potential target genes for the therapy of NSCLC. Among the eleven genes, TINAGL1 and B3GALNT1 are possible candidates for drug compounds that inhibit their gene expression.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Carcinoma, Non-Small-Cell Lung / drug therapy
  • Carcinoma, Non-Small-Cell Lung / genetics*
  • Carcinoma, Non-Small-Cell Lung / pathology*
  • Cell Line, Tumor
  • DNA Methylation / drug effects
  • DNA Methylation / genetics
  • Extracellular Matrix Proteins / genetics*
  • Gene Expression Regulation, Neoplastic / drug effects
  • Humans
  • Lipocalins / genetics*
  • Lung Neoplasms / drug therapy
  • Lung Neoplasms / genetics*
  • Lung Neoplasms / pathology*
  • Molecular Targeted Therapy*
  • N-Acetylgalactosaminyltransferases / genetics*
  • Neoplasm Metastasis
  • Principal Component Analysis
  • Promoter Regions, Genetic / drug effects
  • Promoter Regions, Genetic / genetics
  • Survival Analysis

Substances

  • Extracellular Matrix Proteins
  • Lipocalins
  • TINAGL1 protein, human
  • B3GALNT1 protein, human
  • N-Acetylgalactosaminyltransferases